Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1

Status

Completed 70Unknown 29Active not recruiting 11Terminated 9Recruiting 5Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Pathologic Complete Response 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Epirubicin × Clear all
NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01327521 2012-06-11

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Stanford University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡